Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lishui
Clinical trial register · China

Clinical Trials in Lishui, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Yu jiren4 Second Affiliated Hospital, Zhejiang University, School of Medicine3 Eli Lilly and Company3 Sir Run Run Shaw Hospital2 Zhejiang Cancer Hospital2
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Lishui

42 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
First Affiliated Hospital of Zhejiang University
Observational
10,000
Hangzhou, Lishui
2026-10-31
Recruiting
Capital Medical University
Phase 2
204
Anyang, Beijing, Huzhou, Jiuquan, Lishui, Shangqiu, Suzhou, Taizhou
2026-09-06
Recruiting
Changchun BCHT Biotechnology Co.
Phase 2
420
Lishui
2026-08-12
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
78
Guangzhou, Suqian, Shanghai, Hangzhou, Lishui
2026-06-25
Recruiting
Whole-life Investigation of Lishui Longevity
NCT07592962Ischemic Stroke, Chronic Disease, Cardiovascular
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital
Observational
4,500
Lishui
2026-05-18
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
282
Fuyang, Hefei, Lu'an, Liuzhou, Lishui
2026-01-06
Active, closed
Zhejiang Provincial Center for Disease Control and Prevention
Phase 4
400
Lishui
2025-12-20
Recruiting
Zhejiang University
Not applicable
410
Beijing, Jinjiang, Hangzhou, Lishui, Taizhou
2025-10-24
Recruiting
Zhejiang University
Observational
5,000
Hangzhou, Jiaxing, Lishui
2025-08-03
Recruiting
Sichuan Provincial People's Hospital
Early Phase 1
90
Lishui
2025-07-28
Recruiting
Effectiveness of DITM Versus IMT in COPD Patients
NCT06958666COPD (Chronic Obstructive Pulmonary Disease)
Sir Run Run Shaw Hospital
Not applicable
410
Hangzhou, Lishui, Taizhou
2025-06-30
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
7
Lishui
2025-05-13
Active, closed
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Recruiting
Zhejiang Raygene Pharmaceuticals Co., Ltd
Phase 2/3
300
Nanjing, Lishui
2025-03-27
Recruiting
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
NCT06955143Acute Coronary Syndrome, Chronic Coronary Syndrome
Second Affiliated Hospital of Wenzhou Medical University
Observational
310
Lishui
2025-03-11
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
Zhifeng Tian,MD
Phase 2
38
Lishui
2025-01-08
Not yet open
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Recruiting
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Recruiting
The Central Hospital of Lishui City
Not applicable
30
Jinhua, Lishui
2024-12-10
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08-01
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
1,860
Dongyang, Hangzhou, Jinhua, Lishui, Ningbo, Quzhou, Taizhou, Wenling
2024-06-19
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
216
Huzhou, Lishui, Meicheng, Ningbo, Shaoxing, Taizhou
2024-05-31
Active, closed
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
188
Shenyang, Linyi, Qingdao, Jinan, Lishui, Beijing
2024-04-24
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
DrugsSerplulimab·Oxaliplatin
Yu jiren
Phase 2
314
Hangzhou, Lishui, Ningbo, Taizhou
2023-12-24
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
2,000
Hangzhou, Huzhou, Jiaxing, Lanxi, Lishui, Pinghu, Taizhou, Wenzhou
2023-09-25
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
DrugsToripalimab·Oxaliplatin
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
Sir Run Run Shaw Hospital
Not applicable
422
Hangzhou, Huzhou, Jinhua, Lishui, Ningbo, Quzhou, Shaoxing, Taizhou
2023-07-01
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
DrugsToripalimab·Oxaliplatin
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
DrugsFLOT·Trastuzumab·Toripalimab
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Recruiting
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Active, closed
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Recruiting
Westlake Longevity Cohort
NCT05256251Aging
Westlake University
Observational
2,800
Lishui
2021-11-15
Recruiting
Zhejiang Cancer Hospital
Phase 3
455
Hangzhou, Jinhua, Lishui, Ningbo, Taizhou, Wanzhou
2021-08-02
Recruiting
China Longitudinal Aging and Cognitive Impairment Study
NCT05468905Aging, Mild Cognitive Impairment, Alzheimer Disease, Neurodegeneration
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
4,000
Hangzhou, Lishui
2021-01-10
Recruiting
xuexin he
Not applicable
183
Hangzhou, Jiaxing, Lishui
2020-05-09
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Beijing, Chongqing, Jiamusi, Ji’an, Kaifeng, Liaocheng, Lishui, Nanchang
2016-12
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/lishui

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies with a site in Lishui.

How many clinical trials are recruiting in Lishui?

31 of the 42 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 7 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lishui), 42 studies
PhaseStudiesRecruitingShare
Not applicable10723.8%
Phase 29721.4%
Observational8719%
Phase 38419%
Phase 1/2224.8%
Phase 4214.8%
Early Phase 1112.4%
Phase 1112.4%
Phase 2/3112.4%

Most active sponsors

Lead sponsors with the most studies (Lishui)
Lead sponsorStudiesRecruiting
Yu jiren42
Eli Lilly and Company30
Second Affiliated Hospital, Zhejiang University, School of Medicine32
First Affiliated Hospital of Zhejiang University21
Second Affiliated Hospital of Wenzhou Medical University22
Sir Run Run Shaw Hospital22
The Affiliated People's Hospital of Ningbo University22
Zhejiang Cancer Hospital22
Zhejiang University22
Basilea Pharmaceutica11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.